Actively Recruiting
AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2025-12-04
15000
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
By harnessing artificial intelligence to decode the 12-lead electrocardiogram, the project will enable precise ECG-based phenotyping of hypertrophic cardiomyopathy-accurately classifying septal, apical, and other morphologic subtypes-while simultaneously differentiating HCM from hypertensive heart disease, aortic stenosis, and other phenocopy disorders.
CONDITIONS
Official Title
AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 218 years or older.
- Diagnosed with hypertrophic cardiomyopathy according to the 2023 Chinese Guidelines for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy in Adults.
- Adults with left ventricular wall thickness of 13 mm or greater on echocardiography (HCM phenocopy cohort).
- Adults with no history of cardiac disease and no evidence of myocardial hypertrophy on echocardiography (healthy-control cohort).
You will not qualify if you...
- Patients from whom analyzable ECG data cannot be obtained.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310009
Actively Recruiting
Research Team
X
Xiaojie Xie, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here